Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of “Buy” by Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $50.5714.

A number of equities analysts have weighed in on the stock. Scotiabank reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Wells Fargo & Company dropped their price target on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. Canaccord Genuity Group dropped their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Wall Street Zen upgraded shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Leerink Partners lowered their target price on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating on the stock in a report on Friday, August 22nd.

Hedge Funds Weigh In On Arcturus Therapeutics

Several hedge funds have recently modified their holdings of ARCT. MetLife Investment Management LLC lifted its holdings in shares of Arcturus Therapeutics by 21.5% in the fourth quarter. MetLife Investment Management LLC now owns 16,676 shares of the biotechnology company’s stock worth $283,000 after buying an additional 2,955 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Arcturus Therapeutics by 11.8% in the fourth quarter. Hsbc Holdings PLC now owns 25,368 shares of the biotechnology company’s stock worth $424,000 after buying an additional 2,673 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Arcturus Therapeutics by 7.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock worth $323,000 after buying an additional 1,279 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Arcturus Therapeutics by 5.6% in the fourth quarter. Northern Trust Corp now owns 256,332 shares of the biotechnology company’s stock worth $4,350,000 after buying an additional 13,582 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Arcturus Therapeutics by 5.0% in the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock worth $316,000 after buying an additional 883 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

ARCT opened at $17.01 on Monday. The firm has a market cap of $461.99 million, a P/E ratio of -7.63 and a beta of 2.38. Arcturus Therapeutics has a 1-year low of $8.04 and a 1-year high of $25.88. The company has a 50 day simple moving average of $14.58 and a two-hundred day simple moving average of $13.36.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.77. The business had revenue of $28.30 million during the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. Equities analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.